TCGA-DK-A3IV-01A-22R-A21D-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 9.658344284
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.570
- INTERFERON_GAMMA_RESPONSE+0.460
- G2M_CHECKPOINT+0.340
- MITOTIC_SPINDLE+0.310
- E2F_TARGETS+0.300
- PROTEIN_SECRETION+0.300
- ALLOGRAFT_REJECTION+0.180
- PI3K_AKT_MTOR_SIGNALING+0.130
- HEME_METABOLISM+0.120
- ANDROGEN_RESPONSE+0.090
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.680
- ANGIOGENESIS-0.620
- HEDGEHOG_SIGNALING-0.440
- MYOGENESIS-0.440
- HYPOXIA-0.430
- OXIDATIVE_PHOSPHORYLATION-0.410
- COAGULATION-0.370
- APICAL_JUNCTION-0.360
- WNT_BETA_CATENIN_SIGNALING-0.360
- PANCREAS_BETA_CELLS-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 17-071pB9_FFPE | — | — | 0.881 |
| 2 | SRR8613806 | — | D | 0.865 |
| 3 | TCGA-78-7143-01A-11R-2039-07 | — | cohortA1 | 0.855 |
| 4 | TCGA-95-7947-01A-11R-2187-07 | — | cohortA1 | 0.818 |
| 5 | s0122212 | — | — | 0.815 |
| 6 | aMVAC.P_006_TURBT_S224 | — | — | 0.814 |
| 7 | SRR10899995 | — | — | 0.812 |
| 8 | TCGA-S3-A6ZF-01A-32R-A32P-07 | — | B | 0.811 |
| 9 | 6b375859-116e-4a5e-b5b4-994a56cc9a75 | — | — | 0.810 |
| 10 | ERR2208907 | — | — | 0.805 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.570 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.180 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.090 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.060 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.010 | Idelalisib | — uncovered |